Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361766 | 0.82 | CHRNB2 (0.59) | CHRNB2CHRNA4MAPTHRH3LTA4H | |
| SCHEMBL14572016 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA4MAPTHRH3LTA4H | |
| SCHEMBL26796046 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA4MAPTHRH3LTA4H | |
| SCHEMBL29340538 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA4MAPTHRH3LTA4H | |
| SCHEMBL14308132 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4HRH3LTA4HKEAP1 | |
| SCHEMBL25903640 | 0.76 | CHRNB2 (0.46) | CHRNB2CHRNA4MAPTHRH3LTA4H | |
| SCHEMBL17918919 | 0.76 | LTA4H (0.41) | MAPTLTA4H | |
| SCHEMBL19503414 | 0.74 | ALDH1A1 (0.46) | MAPT | |
| SCHEMBL16330599 | 0.74 | CYP2D6 (0.47) | MAPTLTA4H | |
| SCHEMBL31445086 | 0.74 | TAAR1 (0.46) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | CHRNB2 4699/4885CHRNA4 4867/4885MAPT 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.